KDDF’s Support Reflected In Robust R&D, Licensing By Korean Firms
Executive SummaryVarious government support schemes seem to have led to recent successful new drug development activities and licensing deals by South Korean pharma and biotech firms. The state-run Korea Drug Development Fund is seen as having played a key role in this effort, providing assistance to 153 R&D programs in the country so far to speed up development of novel and innovative global medicines.
You may also be interested in...
Scrip takes a look at Korean out-licensing deal trends and rankings in 2018, finding biotech-related transactions were dominant.
The South Korean pharma industry and government are notching up efforts to pursue open innovation for successful R&D, and the state-run Korea Drug Development Fund (KDDF) is at the center of this push. The CEO of the fund, which is supported by multiple government ministries, talks to PharmAsia News about how it is supporting domestic firms to more successfully acquire and develop novel global drugs.